SAN DIEGO, June 30, 2026
Aspen Neuroscience, Inc. has announced the successful completion of Cohort 3 and Cohort 4 dosing in its ongoing Phase 1/2a ASPIRO clinical trial evaluating sasineprocel (ANPD001), a personalized autologous induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of Parkinson’s disease (PD). The milestone marks a significant advancement in the clinical development of one of the most advanced autologous regenerative therapies for Parkinson’s disease currently under investigation in the United States. With the completion of these cohorts, 15 patients have now been dosed in the ASPIRO study, representing one of the largest reported clinical experiences involving an autologous cell therapy for Parkinson’s disease. The latest cohorts also introduce Aspen’s commercial-ready cryopreserved “thaw-and-inject” formulation, an important innovation designed to improve manufacturing scalability, simplify clinical administration, and support the company’s planned transition toward Phase 3 clinical development. The achievement reinforces Aspen Neuroscience’s commitment to advancing regenerative medicine solutions capable of addressing the underlying causes of neurodegenerative disease rather than simply managing symptoms.
Commercial-Ready Cell Therapy Supports Phase 3 Preparation
The completion of Cohorts 3 and 4 represents more than a clinical enrollment milestone, as both groups utilize Aspen’s commercial-ready formulation of sasineprocel, specifically developed to support large-scale manufacturing and future commercialization. Unlike earlier formulations, the updated product features a cryopreserved “thaw-and-inject” drug product, allowing personalized therapeutic cells to be administered immediately after arrival at the treatment center without requiring extensive on-site preparation.
This streamlined approach improves procedural efficiency while enabling more consistent manufacturing, distribution, and clinical delivery across multiple treatment centers. Aspen believes this manufacturing innovation is a critical step toward supporting future pivotal Phase 3 studies and eventual commercial deployment, helping establish a reproducible production process that meets regulatory and clinical requirements for personalized regenerative therapies.
Autologous iPSC Therapy Targets Disease Modification
Advertisement
The ASPIRO Phase 1/2a trial is an open-label clinical study designed to evaluate the safety, tolerability, and potential efficacy of sasineprocel, a single-dose autologous iPSC-derived dopaminergic neuron precursor cell (DANPC) therapy. Unlike conventional Parkinson’s disease treatments that primarily alleviate symptoms by replacing dopamine pharmacologically, sasineprocel is designed to replace lost dopamine-producing neurons and reconstruct damaged neural circuitry, potentially modifying disease progression itself.
The therapy begins with a small skin biopsy, allowing a patient’s own cells to be reprogrammed into induced pluripotent stem cells, differentiated into dopaminergic neuron precursor cells, and precisely delivered into the putamen, the brain region responsible for dopamine signaling. Because the therapy is autologous, using each patient’s own cells, it eliminates the need for long-term immunosuppressive therapy commonly required with donor-derived cell treatments. Sasineprocel has also received FDA Fast Track designation, reflecting its potential to address a significant unmet medical need in Parkinson’s disease.
Regenerative Medicine Continues to Transform Parkinson’s Treatment
Aspen Neuroscience continues advancing critical activities supporting late-stage clinical development, including manufacturing scale-out, process optimization, and commercial readiness in preparation for future pivotal trials. Parkinson’s disease affects millions of people worldwide and remains a progressive neurodegenerative disorder with limited disease-modifying treatment options. Regenerative medicine approaches such as autologous stem cell therapies represent a promising new frontier by targeting the biological causes of neuronal loss rather than simply controlling symptoms.
With one of the largest clinical experiences reported for an autologous Parkinson’s cell therapy and continued progress toward scalable manufacturing, Aspen Neuroscience is strengthening its position as a leader in regenerative medicine innovation. The successful completion of Cohorts 3 and 4 demonstrates important progress toward developing a personalized, potentially disease-modifying therapy that could transform the future treatment landscape for patients living with Parkinson’s disease.
Source: Aspen Neuroscience press release
